Invasive Breast Cancer Treated with Taxol and Epirubicin Neo-adjuvant Chemotherapy: The Role in the Outcome of the "Crosstalk" between Erb receptors and p53

David Sarid, Ilan G. Ron, Lior Shoshan, Itai Barnea, Sima Shina, Mimi Baratz, Julia Greenberg, Ofer Merimskyi, Rami Ben-Yosef, Shahar Lev-Ari, Affa Keidar, Neora Yaal-Hahoshen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Purpose: To correlate p53 and ErbB receptors status with disease-free survival (DFS) and overall survival (OS) in locally advanced breast cancer. Patients and Methods: Sixty patients were included in a single-center, open-label, phase II trial (1998-2003). Analysis of Erb receptors and p53 status and estrogen receptor/progesterone receptor data were available for 33 patients. Neoadjuvant epirubicin 75 mg/m2 and paclifaxel 175-200 mg/m2 were administered every 21 days. The patients underwent surgery and radiation therapy and adjuvant chemo/hormonotherapy. Results: Approximately two thirds of the patients demonstrated overexpression of ErbB receptors and had mutant p53 overexpression. The disease recurred in 11133 patients and 7 died (median follow-up 56 months). Detrimental effects on OS were established in cases of combined defective p53 expression and ErbB1-ErbB3 heterodimeric receptor overexpression. In contrast, normal p53 together with the same overexpressed heterodimeric combination of ErbB receptors showed no statistically significant effect. Conclusion: In terms of the clinical impact of combinations of ErbB receptors with or without mutant p53, only the overexpressed various ErbBl-ErbB3 dimeric combinations and the ErbB1/ErbB2/ErbB3 triplet combination with mutated p53 were related to a significantly poorer outcome. This observation may help in the development of new strategies required for blocking these molecular pathways and improving the outcome of patients with locally advanced breast cancer.

Original languageEnglish
Pages (from-to)3147-3152
Number of pages6
JournalAnticancer Research
Volume28
Issue number5 B
StatePublished - Sep 2008

Keywords

  • Breast
  • Epirubicin
  • Erb family
  • Neoadjuvant chemotherapy
  • P53
  • Taxol

Fingerprint

Dive into the research topics of 'Invasive Breast Cancer Treated with Taxol and Epirubicin Neo-adjuvant Chemotherapy: The Role in the Outcome of the "Crosstalk" between Erb receptors and p53'. Together they form a unique fingerprint.

Cite this